SGLT2i reduces risk of developing HCC in patients with co-existing T2D and CHB infection – A territory-wide cohort study in Hong Kong
Hepatology（2023）
摘要
Among patients with co-existing T2D and CHB, SGLT2i use was associated with a lower risk of incident HCC.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要